Heartbeat: improved diagnosis of familial hypercholesterolaemia

doi:10.1136/heartjnl-2021-319928

Catherine M Otto

Familial hypercholesterolaemia (FH) is the most common autosomal dominant genetic condition, affecting about 1 in 250 people, caused by a pathogenic variant in one of several genes involved in lipoprotein cholesterol catabolism. Treatment of elevated serum low-density lipoprotein cholesterol in people with FH substantially reduces the risk of ischaemic heart disease and cardiovascular mortality. Yet, the vast majority of FH cases are undiagnosed and, thus, untreated. Diagnosis is challenging because patients typically are asymptomatic, may not know their family history, are unaware of the seriousness of the diagnosis and may not even be seeing a physician regularly. In addition, the phenotypic diagnosis requires more than just serum cholesterol levels.

In this issue of *Heart*, Carvalho and colleagues¹ demonstrated the feasibility of the FH Case Ascertainment Tool (FAMCAT) for identifying patients likely to have FH in a cohort of 777 128 primary care patients in London. The FAMCAT score is based on systematic screening of routine primary care records for cholesterol measurements, age, triglycerides, family history, diabetes, kidney disease and current use of lipid-lowering drugs (figure 1). The use of FAMCAT to identify patients likely to have FH could ensure more accurate and rapid diagnosis (and subsequent treatment) for this group of patients at high risk of cardiovascular disease.

A different approach to detection of FH was used by Brett and colleagues² in a cohort of 232, 139 Australian general practice patients. Using a pragmatic two-step approach, they first identified those at higher risk of FH using the TAR-B-Ex electronic screening tool. Then, in the 1843 (0.8%) of patients identified electronically by TAR-B-Ex, clinical assessment by the physician was used to confirm a high FH risk based on the phenotypic Dutch Lipid Clinic Network Criteria score. In a subset of 77 patients with FH, subsequent intensification of lipid-lowering therapy

Figure 1 Risk of familial hypercholesterolaemia (FH) in inner East London calculated using FAMCAT algorithm, assuming population prevalence of 1 in 500 and 1 in 250. IHD, ischaemic heart disease; PP, population prevalence.

led to a further reduction in serum cholesterol levels.

In an editorial, Qureshi and Patel³ summarise methods using the electronic health record (EHR) for improved diagnosis of FH (figure 2) and point out that the EHR approach often is limited by inadequate or missing data about family history, physical signs and other information. Cholesterol levels, while not diagnostic in isolation, are essential for the diagnosis but may not have been measured in many asymptomatic individuals. They conclude: 'Ultimately, successfully identifying the thousands of people with FH in the UK and abroad will require a system-wide approach from opportunistic identification at routine health encounters, systematic case finding in primary care, screening people at the time of a premature CVD event to child-parent screening and cascade testing.'

Also, in this issue of *Heart*, Schwerzmann and colleague⁴ report clinical outcomes in 105 patients adult congenital heart disease (ACHD) with COVID-19 infections. Overall, 5 patients died and 13 had a complication disease course. Clinical features associated with a complicated disease course were similar to the general population including older age, the presence of two or more comorbidities, and obesity (figure 3). In addition, those with a complicated disease course were more likely to have cyanotic heart disease such as unrepaired cyanotic defects are Eisenmenger syndrome, compared with ACHD patients with an uncomplicated COVID-19 course (OR 60, 95% CI 7.6 to 474).

Yuan and Oechslin comment in an editorial⁵ that 'Contrary to our previous conceptualisation of risk, anatomical complexity does not appear to predict

Figure 2 Pathway to identification of FH from primary care. CVD, cardiovascular disease; DLCN, Dutch Lipid Clinic Network; FAMCAT, FH Case Ascertainment Tool; FH, familial hypercholesterolaemia; GP, general practitioner; HCA, healthcare assistant; LLT, lipid-lowering treatment; VUS, variant of unknown significance.

Division of Cardiology, University of Washington, Seattle, Washington, USA

Correspondence to Professor Catherine M Otto, Division of Cardiology, University of Washington, Seattle, WA 98195, USA; cmotto@uw.edu

Figure 3 Univariable significant COVID-19 risk factors in patients with adult congenital heart disease and the corresponding ORs. We propose to stratify patients based on age, number of comorbidities, weight and presence of a high-risk cardiac lesion (cyanotic heart disease). BMI, body mass index.

severe infection or death. Rather, patient-specific risk factors similar to those in the non-CHD cohort remain important, while strong CHD-specific risk factors for severe illness or death after COVID-19 infection were cyanotic heart disease and physiological stage. These results help us to tailor patient recommendations but require further confirmation in large international, multicentre studies that are sufficiently powered to answer our remaining questions.⁹

A meta-analysis by Imazio and colleagues⁶ supports the efficacy of anti-interleukin-1 agents, such as anakinra and rilonacept, for prevention of recurrent episodes of pericarditis in patients with corticosteroid-dependent and

colchicine-resistant recurrent pericarditis. Anthony and Collier⁷ remind us that recurrent pericarditis complicates 15%–30% of index cases of pericarditis; the clinical consequences, in addition to pain, can be serious including recurrent effusions, tamponade physiology and constrictive pericarditis; and there is little data on effective therapies (figure 4).⁸ They conclude ‘Inhibition of the IL-1 pathway may represent a paradigm shift in the treatment of patients with recurrent pericarditis despite standard therapy. However, larger RCT data are required for further validation of the efficacy and safety of these novel medications in the treatment of recurrent pericarditis.’

The *Education in Heart* article in this issue provides a quick overview of cardio-oncology for the general cardiologist. Cardio-oncology is defined as ‘the treatment and prevention of cardiovascular disease in cancer patients both during oncology treatment and afterwards.’⁹

A basic understanding of cardio-oncology now is considered core knowledge for every cardiologist, given the demographic overlap in the prevalence of cardiovascular disease and cancer, in addition to the potential cardiotoxic effects of cancer treatments. The information and practical advice in this review article are a concise resource for busy practitioners.

Our short *Cardiology in Focus* article¹⁰ provides a brief overview of cost-effectiveness methodology, with a short list of references for those who wish to dive deeper into this topic.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Otto CM. *Heart* 2021;**107**:1185–1187.

Heart 2021;**107**:1185–1187.
doi:10.1136/heartjnl-2021-319928

CRP, C-reactive protein; DAMP, damage-associated molecular patterns; IL, interleukin; PAMP, pathogen-associated molecular patterns
Brucato A, et al. *Int Emerg Med*. 2018. <https://doi.org/10.1007/s11739-018-1907-x>; Dinarello CA, et al. *Nat Rev Drug Discov*. 2012.

Figure 4 Interleukin-1 alpha and beta in pericardial inflammation. Adapted from Klein *et al.*⁸

ORCID iD

Catherine M Otto <http://orcid.org/0000-0002-0527-9392>

REFERENCES

- 1 Carvalho C, Williams C, Raisi-Estabragh Z. Application of a risk stratification tool for familial hypercholesterolaemia in primary care: an observational cross-sectional study in an unselected urban population. *Heart* 2021;107:1220–5.
- 2 Brett T, Chan DC, Radford J, *et al*. Improving detection and management of familial hypercholesterolaemia in Australian general practice. *Heart* 2021;107:1213–9.
- 3 Qureshi N, Patel RS. Hiding in plain sight: supporting primary care to find familial hypercholesterolaemia and save lives. *Heart* 2021;107:1190–2.
- 4 Schwerzmann M, Ruperti-Repilado FJ, Baumgartner H. Clinical outcome of COVID-19 in patients with adult congenital heart disease. *Heart* 2021;107:1226–32.
- 5 Yuan S, Oechslin E. Anatomical complexity does not predict outcomes after COVID-19 in adults with congenital heart disease. *Heart* 2021;107:1193–5.
- 6 Imazio M, Andreis A, Piroli F, *et al*. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. *Heart* 2021;107:1240–5.
- 7 Anthony C, Collier P. Anti-Interleukin-1 for recurrent pericarditis; maybe a fix (but prior studies do not really mix). *Heart* 2021;107:1196–8.
- 8 Klein AL, Imazio M, Brucato A, *et al*. RHAPSODY: rationale for and design of a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1 α and interleukin-1 β trap, in patients with recurrent pericarditis. *Am Heart J* 2020;228:81–90.
- 9 Tan L-L, Lyon AR. Cardio-oncology for the general cardiologist. *Heart* 2021;107:1254–66.
- 10 Ferro EG, Liu C-L, Kazi DS. Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. *Heart* 2021;107:1267–8.